Want to see BIOA full AI Analyst Report?
BIOA Stock Chart & Stats
$10.11
$0.56(2.57%)
At close: 4:00 PM EDT
$10.11
$0.56(2.57%)
Day’s Range― - ―
52-Week Range$5.04 - $25.96
Previous CloseN/A
Volume15.03K
Average Volume (3M)641.09K
Market Cap
$312.56M
Enterprise Value$783.09
Total Cash (Recent Filing)$318.75M
Total Debt (Recent Filing)$2.83M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Nov 05, 2026EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.38
Shares Outstanding45,896,908
10 Day Avg. Volume854,590
30 Day Avg. Volume641,087
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)1.75
Price to Sales (P/S)52.85
P/FCF Ratio-5.77
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$35.63Price Target Upside252.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.43
Revenue Forecast (FY)$7.60M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue growth and early commercialization provide evidence that BioAge is beginning to build a business beyond pure discovery. Although the base remains small, continued top-line expansion could improve operating leverage and support broader development investment over the next several quarters.
Low Balance-Sheet LeverageVery low leverage gives BioAge meaningful financial flexibility relative to its current operating profile. Limited debt reduces near-term balance-sheet pressure and interest burden, allowing management to direct more resources toward research, clinical development, and commercialization activities.
Clinical Pipeline AdvancementAdvancing BGE-102 into a randomized Phase 2 study represents a material step in validating BioAge’s therapeutic pipeline. The trial’s controlled design, combination and monotherapy arms, and planned retinal and biomarker measures can generate clinically relevant evidence for future expansion.
Bears Say
Deep Operating LossesThe company’s revenue base remains far too small to absorb its research and operating costs, producing substantial ongoing losses. Unless revenue scales materially or spending becomes more efficient, persistent negative margins could continue eroding equity and constrain long-term strategic flexibility.
Heavy Cash BurnLarge operating and free-cash-flow outflows show that BioAge is consuming significant resources to fund its business. Continued burn increases reliance on existing reserves or future financing, potentially creating funding pressure and limiting the pace or breadth of clinical investment.
Mid-Stage Clinical RiskBGE-102 remains in a mid-stage trial, with topline data not expected until the second half of 2027. This leaves the program exposed to clinical execution and efficacy uncertainty over the medium term, while substantial development spending continues before pivotal validation.
BioAge Labs, Inc. News
BIOA FAQ
What was BioAge Labs, Inc.’s price range in the past 12 months?
BioAge Labs, Inc. lowest stock price was $5.04 and its highest was $25.95 in the past 12 months.
What is BioAge Labs, Inc.’s market cap?
BioAge Labs, Inc.’s market cap is $312.56M.
When is BioAge Labs, Inc.’s upcoming earnings report date?
BioAge Labs, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 33 days.
How were BioAge Labs, Inc.’s earnings last quarter?
BioAge Labs, Inc. released its earnings results on Aug 05, 2026. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.607 by $0.027.
Is BioAge Labs, Inc. overvalued?
According to Wall Street analysts BioAge Labs, Inc.’s price is currently Undervalued.
Does BioAge Labs, Inc. pay dividends?
BioAge Labs, Inc. does not currently pay dividends.
What is BioAge Labs, Inc.’s EPS estimate?
BioAge Labs, Inc.’s EPS estimate is -0.62.
How many shares outstanding does BioAge Labs, Inc. have?
BioAge Labs, Inc. has 45,896,908 shares outstanding.
What happened to BioAge Labs, Inc.’s price movement after its last earnings report?
BioAge Labs, Inc. reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.607. Following the earnings report the stock price went up 2.641%.
Which hedge fund is a major shareholder of BioAge Labs, Inc.?
Currently, no hedge funds are holding shares in BIOA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioAge Labs, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.63 (252.37% Upside)
$35.63 (252.37% Upside)
Blogger Sentiment
Neutral
BIOA Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 20.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
15.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
BioAge Labs, Inc.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
BIOA Stock 12 Month Forecast
Average Price Target
$35.63
▲(252.37% Upside)
Technical Analysis
Ironwood Pharma
―
Lifecore Biomedical
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
Incannex Healthcare Limited Sponsored ADR
―
Ownership Overview
9.25% Insiders
6.21% Mutual Funds
46.99% Other Institutional Investors
25.98% Public Companies and
Individual Investors